ইস্রায়েল - হিব্রু - Ministry of Health

merck sharp & dohme (israel - 1996) company ltd, israel - aprepitant - קפסולות - aprepitant 80 mg - aprepitant - aprepitant - emend in combination with other antiemetic agents is indicated for the: - prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy including high-dose cisplatin. - prevention of nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy.

ইস্রায়েল - হিব্রু - Ministry of Health

merck sharp & dohme israel ltd - aprepitant - קפסולות - aprepitant 125 mg - aprepitant - aprepitant - emend in combination with other antiemetic agents is indicated for the: - prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy including high-dose cisplatin. - prevention of nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy.

ইস্রায়েল - হিব্রু - Ministry of Health

merck sharp & dohme (israel - 1996) company ltd, israel - aprepitant - קפסולות - aprepitant 125 mg - aprepitant - aprepitant - emend in combination with other antiemetic agents is indicated for the: - prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy including high-dose cisplatin. - prevention of nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy.

ইস্রায়েল - হিব্রু - Ministry of Health

merck sharp & dohme israel ltd - fosaprepitant as fosaprepitant dimeglumine 150 mg - powder for solution for infusion - aprepitant - emend iv 150mg in combination with other antiemetic agents is indicated for the: - prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy including high-dose cisplatin. - prevention of nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy.

ইস্রায়েল - হিব্রু - Ministry of Health

merck sharp & dohme israel ltd - metformin hydrochloride 1000 mg; sitagliptin as monohydrate phosphate 50 mg - tablets - metformin - januet is indicated as an adjunct to diet and exercise to improve glycemic control in adult patients with type 2 diabetes mellitus. important limitations of use:januet should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis, as it would not be effective in these settings.januet has not been studied in patients with a history of pancreatitis. it is unknown whether patients with a history of pancreatitis are at increased risk for the development of pancreatitis while using januet.

ইস্রায়েল - হিব্রু - Ministry of Health

merck sharp & dohme israel ltd - metformin hydrochloride 1000 mg; sitagliptin as monohydrate phosphate 50 mg - tablets - metformin - januet is indicated as an adjunct to diet and exercise to improve glycemic control in adult patients with type 2 diabetes mellitus. important limitations of use:januet should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis, as it would not be effective in these settings.januet has not been studied in patients with a history of pancreatitis. it is unknown whether patients with a history of pancreatitis are at increased risk for the development of pancreatitis while using januet.

ইস্রায়েল - হিব্রু - Ministry of Health

merck sharp & dohme israel ltd - metformin hydrochloride 1000 mg; sitagliptin as monohydrate phosphate 50 mg - tablets - metformin - januet is indicated as an adjunct to diet and exercise to improve glycemic control in adult patients with type 2 diabetes mellitus. important limitations of use:januet should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis, as it would not be effective in these settings.januet has not been studied in patients with a history of pancreatitis. it is unknown whether patients with a history of pancreatitis are at increased risk for the development of pancreatitis while using januet.

ইস্রায়েল - হিব্রু - Ministry of Health

merck sharp & dohme israel ltd - metformin hydrochloride 1000 mg; sitagliptin as monohydrate phosphate 50 mg - tablets - metformin - januet is indicated as an adjunct to diet and exercise to improve glycemic control in adult patients with type 2 diabetes mellitus. important limitations of use:januet should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis, as it would not be effective in these settings.januet has not been studied in patients with a history of pancreatitis. it is unknown whether patients with a history of pancreatitis are at increased risk for the development of pancreatitis while using januet.

ইস্রায়েল - হিব্রু - Ministry of Health

merck sharp & dohme israel ltd - metformin hydrochloride 500 mg; sitagliptin as monohydrate phosphate 50 mg - tablets - metformin - januet is indicated as an adjunct to diet and exercise to improve glycemic control in adult patients with type 2 diabetes mellitus. important limitations of use:januet should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis, as it would not be effective in these settings.januet has not been studied in patients with a history of pancreatitis. it is unknown whether patients with a history of pancreatitis are at increased risk for the development of pancreatitis while using januet.

ইস্রায়েল - হিব্রু - Ministry of Health

merck sharp & dohme israel ltd - metformin hydrochloride 500 mg; sitagliptin as monohydrate phosphate 50 mg - tablets - metformin - januet is indicated as an adjunct to diet and exercise to improve glycemic control in adult patients with type 2 diabetes mellitus. important limitations of use:januet should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis, as it would not be effective in these settings.januet has not been studied in patients with a history of pancreatitis. it is unknown whether patients with a history of pancreatitis are at increased risk for the development of pancreatitis while using januet.